NAVB
(NYSE)
2.62
+0.0614  (+2.34%)
Volume (24h): 694.51K Day Range: 2.45 - 2.63
Market Cap: 56.71M 52W Range: 0.4998 - 3.50
May-26-20 02:11PM Company News for May 26, 2020Zacks
May-22-20 08:25PM Stocks close steady but post gains for the week ahead of U.S. Memorial Day holidayMarketWatch
12:35PM Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial dataMarketWatch
May-22-20 11:10AM The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID FrayBenzinga
May-21-20 08:30PM Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid ArthritisBusiness Wire
May-15-20 07:29AM Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMTThomson Reuters StreetEvents
May-14-20 08:01PM Navidea Biopharmaceuticals Reports First Quarter 2020 Financial ResultsBusiness Wire
May-11-20 11:30AM Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®Business Wire
May-07-20 11:00AM Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate UpdateBusiness Wire
Apr-22-20 11:30AM Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 PandemicBusiness Wire
Apr-21-20 12:52PM What You Must Know About Navidea Biopharmaceuticals, Inc.'s (NYSEMKT:NAVB) Beta ValueSimply Wall St.
Mar-31-20 11:30AM Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business UpdatesBusiness Wire
Mar-24-20 08:19PM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
02:37PM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-23-20 08:10AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
02:48AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-20-20 11:00AM Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®Business Wire
Mar-12-20 07:00AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-11-20 08:05PM Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial ResultsBusiness Wire
07:00PM Navidea Biopharmaceuticals, Inc. to Host Earnings CallACCESSWIRE
Mar-04-20 01:00PM Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate UpdateBusiness Wire
Feb-21-20 01:42PM Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) SharesSimply Wall St.
Feb-14-20 04:56PM Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsBusiness Wire
12:28PM Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional FundingBusiness Wire
Feb-12-20 02:20PM Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97%Simply Wall St.
Dec-30-19 10:19PM Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New YorkBusiness Wire
Dec-14-19 02:41PM The of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More SharesSimply Wall St.
Dec-06-19 11:23PM Navidea Biopharmaceuticals Announces $1.9 Million Private PlacementBusiness Wire
Dec-05-19 08:45PM Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main EventBusiness Wire
Dec-02-19 07:08PM Navidea Biopharmaceuticals Wins Summary Judgment in OhioBusiness Wire
Nov-20-19 03:41AM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-14-19 01:30PM Navidea Biopharmaceuticals to Present at the PCG Spotlight Series ConferenceBusiness Wire
Nov-13-19 12:38PM What Kind Of Shareholders Own Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)?Simply Wall St.
Nov-07-19 09:05PM Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial ResultsBusiness Wire
12:30PM Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based ImmunotherapiesBusiness Wire
Oct-31-19 11:30AM Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate UpdateBusiness Wire
Oct-29-19 11:30AM Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid ArthritisBusiness Wire
Oct-14-19 07:42PM Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMTThomson Reuters StreetEvents
Jun-24-19 11:46AM Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study ResultsBusiness Wire
Jun-22-19 07:07PM The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOsBenzinga
Jun-18-19 08:05PM Navidea Biopharmaceuticals Announces Closing of Public Offering of Common StockBusiness Wire
05:30PM Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMTThomson Reuters StreetEvents
May-08-19 10:28PM Navidea: 1Q Earnings SnapshotAssociated Press
Nov-15-18 12:40PM Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences — Renewed Outlook, Key Drivers of GrowthGlobeNewswire
Nov-07-18 11:45PM Navidea: 3Q Earnings SnapshotAssociated Press
Sep-18-18 12:44PM The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer SharesBenzinga
Aug-16-18 11:47AM What Does Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) Ownership Structure Look Like?Simply Wall St.
Aug-08-18 11:05PM Navidea: 2Q Earnings SnapshotAssociated Press
May-07-18 08:05PM Navidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmithACCESSWIRE
Apr-05-18 11:00AM Wired News – EMA to Review Regeneron’s Marketing Authorization Application for CemiplimabACCESSWIRE
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)